First Mercantile Trust Co. Sells 11,643 Shares of Merck & Co., Inc. (MRK)

Share on StockTwits

First Mercantile Trust Co. lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 74.4% during the fourth quarter, HoldingsChannel reports. The firm owned 4,010 shares of the company’s stock after selling 11,643 shares during the period. First Mercantile Trust Co.’s holdings in Merck & Co., Inc. were worth $306,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Merck & Co., Inc. by 0.5% in the third quarter. Vanguard Group Inc. now owns 202,833,998 shares of the company’s stock worth $14,389,044,000 after acquiring an additional 924,701 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of Merck & Co., Inc. by 0.5% in the third quarter. Vanguard Group Inc now owns 202,833,998 shares of the company’s stock worth $14,389,044,000 after acquiring an additional 924,701 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Merck & Co., Inc. by 184,252.6% in the third quarter. Bank of New York Mellon Corp now owns 38,985,039 shares of the company’s stock valued at $2,765,600,000 after buying an additional 38,963,892 shares during the last quarter. Capital International Investors increased its holdings in Merck & Co., Inc. by 178.2% in the third quarter. Capital International Investors now owns 32,984,606 shares of the company’s stock valued at $2,339,928,000 after buying an additional 21,127,887 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Merck & Co., Inc. by 64.3% in the third quarter. Janus Henderson Group PLC now owns 20,519,549 shares of the company’s stock valued at $1,455,653,000 after buying an additional 8,032,634 shares during the last quarter. Institutional investors own 72.41% of the company’s stock.

Several analysts recently weighed in on MRK shares. Credit Suisse Group set a $86.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, December 13th. Morgan Stanley set a $81.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, December 20th. Citigroup set a $65.00 price objective on Merck & Co., Inc. and gave the company a “hold” rating in a report on Thursday, December 20th. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $83.00 price objective for the company in a report on Friday, January 4th. Finally, BMO Capital Markets lowered Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price objective for the company. in a report on Wednesday, January 23rd. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $77.06.

In other news, Chairman Kenneth C. Frazier sold 192,736 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $82.05, for a total transaction of $15,813,988.80. Following the completion of the transaction, the chairman now directly owns 990,451 shares of the company’s stock, valued at $81,266,504.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas H. Glocer sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $75.96, for a total value of $759,600.00. The disclosure for this sale can be found here. Insiders have sold 902,060 shares of company stock valued at $71,976,571 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

NYSE:MRK opened at $82.29 on Friday. The company has a market cap of $223.65 billion, a PE ratio of 18.96, a P/E/G ratio of 2.03 and a beta of 0.62. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $83.45. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.17 and a quick ratio of 0.92.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Friday, February 1st. The company reported $1.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.01. The company had revenue of $11 billion during the quarter, compared to analyst estimates of $10.93 billion. Merck & Co., Inc. had a return on equity of 36.83% and a net margin of 14.71%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.98 earnings per share. Equities research analysts anticipate that Merck & Co., Inc. will post 4.65 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.67%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.

ILLEGAL ACTIVITY WARNING: “First Mercantile Trust Co. Sells 11,643 Shares of Merck & Co., Inc. (MRK)” was originally published by Highlight Press and is the sole property of of Highlight Press. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://highlightpress.com/2019/03/24/first-mercantile-trust-co-sells-11643-shares-of-merck-co-inc-mrk.html.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.